Summary
The angiogenesis inhibitor bevacizumab, a VEGF antagonist, was approved in the European Union in August 2007 for the first-line therapy of inoperable, advanced or recurrent non-small-cell lung cancer, in combination with a platin-based chemotherapy regimen. Tumors with predominantly squamous-cell histology must be excluded. Two recent phase-III studies have shown that bevacizumab, combined with carboplatin and paclitaxel (E4599) or cisplatin and gemcitabine (AVAiL), significantly prolongs overall survival and/or progression-free survival. The most common adverse events during therapy with bevacizumab are hypertension and proteinuria – both are usually well manageable. By applying correct patient selection criteria the risk of pulmonary bleeding can be greatly reduced.
Zusammenfassung
Der Angiogenesehemmer Bevacizumab, ein VEGF-Antagonist, erhielt Ende August 2007 eine EU-weite Zulassung für die First-Line-Therapie von Patienten mit inoperablem fortgeschrittenem, metastasiertem oder rezidivierendem nicht-kleinzelligem Bronchialkarzinom in Kombination mit einer Platin-haltigen Chemotherapie. Davon ausgenommen sind Karzinome mit vorwiegender Plattenepithel-Histologie. In zwei rezenten Phase-III-Studien konnte gezeigt werden, dass Bevacizumab in Kombination mit Carboplatin und Paclitaxel (E4599) bzw. Cisplatin und Gemcitabin (AVAiL) das Gesamtüberleben und/oder das progressionsfreie Überleben signifikant verlängert. Die häufigsten Nebenwirkungen von Bevacizumab sind Hypertonie und Proteinurie, die meist gut beherrschbar sind. Durch entsprechende Patientenauswahl lässt sich das Risiko pulmonaler Blutungen deutlich reduzieren.
Similar content being viewed by others
Literatur
Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH (2006) Paclitaxelcarboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355: 2542–2550
Manegold C, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsch V, Leighl N, Mezger J, Archer V, Reck M, the BO17704 study group (2007) Randomised, double-blind multicentre phase III study of bevacizumab in combination with cisplatin and gemcitabine in chemotherapy-naïve patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): BO17704. ASCO Annual Meeting Proceedings Part I. J Clin Oncol 25(Suppl 18S): Abstract LBA7514
Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH; Eastern Cooperative Oncology Group (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346: 92–98
Brown LF, Berse B, Jackman RW, Tognazzi K, Guidi AJ, Dvorak HF, Senger DR, Connolly JL, Schnitt SJ (1995) Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. Hum Pathol 26: 86–91
Brown LF, Berse B, Jackman RW, Tognazzi K, Manseau EJ, Senger DR, Dvorak HF (1993) Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract. Cancer Res 53: 4727–4735
Mattern J, Koomägi R, Volm M (1996) Association of vascular endothelial growth factor expression with intratumoral microvessel density and tumour cell proliferation in human epidermoid lung carcinoma. Br J Cancer 73: 931–934
Seto T, Higashiyama M, Funai H, Imamura F, Uematsu K, Seki N, Eguchi K, Yamanaka T, Ichinose Y (2006) Prognostic value of expression of vascular endothelial growth factor and its flt-1 and KDR receptors in stage I non-small-cell lung cancer. Lung Cancer 53: 91–96
Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, Jablons DM, Langer CJ, DeVore RF 3rd, Gaudreault J, Damico LA, Holmgren E, Kabbinavar F (2004) Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 22: 2184–2191
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Hasenöhrl, N. Bevacizumab in der First-Line-Therapie des fortgeschrittenen NSCLC. Wien Med Wochenschr 157, 576–578 (2007). https://doi.org/10.1007/s10354-007-0491-x
Issue Date:
DOI: https://doi.org/10.1007/s10354-007-0491-x
Keywords
- Bevacizumab
- Angiogenesis inhibitor
- VEGF antagonist
- NSCLC
- Non-small-cell lung cancer
- Platin-based chemotherapy
- E4599
- AVAiL